Literature DB >> 23592853

Reply to "Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!".

Siraya Jaijakul, Luis Ostrosky-Zeichner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23592853      PMCID： PMC3647909          DOI： 10.1128/JCM.03258-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  4 in total

1.  Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!

Authors:  Gennaro De Pascale; Brunella Posteraro; Salvatore Lucio Cutuli; Anselmo Caricato; Domenico Lepore; Mario Tumbarello; Mariano Alberto Pennisi; Maurizio Sanguinetti; Massimo Antonelli
Journal:  J Clin Microbiol       Date:  2013-05       Impact factor: 5.948

2.  Ocular manifestations of candidemia.

Authors:  Astrid M L Oude Lashof; Aniki Rothova; Jack D Sobel; Markus Ruhnke; Peter G Pappas; Claudio Viscoli; Haran T Schlamm; Iwona T Oborska; John H Rex; Bart Jan Kullberg
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

3.  Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis.

Authors:  Charles R Sims; Siraya Jaijakul; John Mohr; Jose Rodriguez; Malcolm Finkelman; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

4.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.